Our latest articles
Early data are promising, but the upcoming phase 2 trial has questions to answer.
With an effective obesity drug already available and more in the pipeline, what hope do devices have?
In targeting a genetic cause of the disease, Lexeo reckons it could outdo anti-amyloid antibodies, but has a long way to go.
The chocolate-to-vitamins giant discovers that launching a drug is hard. Should its biopharma partners be worried?
Does yesterday’s deal with Roivant mean the pharma giant is cooling on TL1A targeting? And what about Prometheus?
The failure of Roche’s Graduate 1 and 2 studies can be explained away by insufficient amyloid clearance.
Keenly awaited results reveal no smoking gun, but lecanemab’s modest activity appears not that different from Aduhelm’s.
TG Therapeutics and Gilead also await a verdict, and Cytokinetics is set for a panel.
For $200m Astrazeneca buys Neogene, and Alaunos’s long-suffering investors can just look on.
Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.